newsfilter
← Earnings
Earnings Releases·

Citius Oncology — Fiscal Q4 2026 Earnings Summary

  • Preliminary, unaudited unit sales to U.S. wholesalers reached 792 units in Q4 2026, a 120% increase from 360 units in the prior quarter, while 950 vials were ordered by prescribing centers compared to 926 in Q3.
  • Management expects Q4 momentum to continue into fiscal 2027 driven by institutional demand, noting the company is more than halfway to its goal of securing formulary status at 100 priority institutions by year-end 2026.
  • The company faces a critical need for substantial additional funds to operate for at least the next 12 months and is assessing its ability to raise capital as a going concern.
  • Complete fiscal 2026 financial results, including revenue and earnings, remain unaudited and are expected to be reported in December 2026 via Form 10-K.
Company
CITIUS ONCOLOGY INC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic